Minerva Neurosciences shares surge 17.98% after-hours following $20M private placement at premium.

Minerva Neurosciences (NERV) surged 17.98% in after-hours trading following the announcement of a $200 million financing initiative to advance its schizophrenia treatment, Roluperidone. The company disclosed plans to leverage the funds for clinical development, signaling progress in its pipeline and bolstering investor confidence. Recent regulatory updates, including FDA acceptance of its New Drug Application (NDA) earlier in the year, had already positioned the stock for volatility, but the new financing provides critical capital to support upcoming trials, reinforcing its market positioning. The move contrasts with unrelated local news about a WWII veteran in Ohio and a football club's victory in India, which hold no bearing on the stock's sector or financial trajectory.